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Abstract 
Purpose: To evaluate the effectiveness of intravenous thrombolysis in combination with nicorandil in 
the treatment of acute ST-segment elevation myocardial infarction (STEMI). 
Methods: Patients who developed acute STEMI and underwent intravenous thrombolysis in the 
hospital were selected and divided into observation group (n = 128) and control group (n = 114). 
Besides thrombolytic therapy, the observation group was also given 20 mg of nicorandil. The control 
group received conventional thrombolytic therapy only. Clinical effects and rehabilitation of patients 
were observed. 
Results: Cardiac troponin I (cTNI) level of the observation group was 4.0 ± 1.5, 8.3 ± 2.8 and 9.8 ± 3.9 
after 4, 12 and 24 h, respectively, which is much lower than 5.8 ± 1.4, 11.4 ± 2.7 and 13.2 ± 4.2 in the 
control group (p < 0.05). ST-segment resolution of observation group was higher (44 ± 14, 52 ± 17, 69 ± 
21 and 80 ± 18) % at different time points, compared with the control group (p < 0.05). The proportion of 
patients with Curtis-Walker score > 3 points, and ventricular wall motion score (4.70 %; 1.38 ± 0.11) in 
the observation group were both lower than those of the control group (21.00 %; 1.43 ± 0.15) (p < 0.05). 
The difference in adverse cardiac events between the observation group (N = 6, 4.70 %) and control 
group (N = 12, 10.50 %) was not statistically significant (p > 0.05) 
Conclusion: Combining intravenous thrombolysis with nicorandil therapy can enhance myocardial 
perfusion level, reduce myocardial damage, improve cardiac function and decrease risk of arrhythmia 
for acute STEMI patients.  
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ST segment elevation myocardial infarction 
(STEMI), a kind of acute myocardial infarction 
(MI), is high in incidence and mortality. Like 
patients with general acute MI, patients who 
develop STEMI also have symptoms of chest 
pain and arrhythmia; but the most representative 
characteristic is a significant elevation of ST-
segment on the electrocardiogram [1]. The 
incidence of STEMI has become increasingly 
high of recent, seriously threatening people’s 
health. It is a key point to timely, continuously 
and thoroughly dredge infarction related blood 
vessels in the treatment of STEMI [2]. 
Percutaneous coronary intervention (PCI) is 
considered as the optimal scheme for recovering 
blood flow of coronary artery as it is effective in 
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opening infarction related coronary artery, 
recovering blood transport and rescuing 
endangered myocardial cells [3]. However, most 
patients with STEMI fail to receive PCI within 
effective time window due to the imbalanced 
distribution of medical resources in China. 
 
It has been found that, thrombolytic therapy is 
still the preferred method for treating STEMI and 
60 % patients tend to accept thrombolytic 
therapy, though PCI is extensively promoted in 
clinic in recently years [4]. Thrombolytic therapy 
is rapid, convenient, economic and easy to 
operate. Thrombolytic therapy can dredge blood 
vessels by resolving thrombus existing in 
coronary artery, thereby recovering blood 
perfusion of tissue and organs partially or 
completely. But it is only effective in opening 
infarction related blood vessels but not beneficial 
for early recovery of cardiac function. Experts in 
China and those from some foreign countries 
have proved that nicorandil is effective in 
protecting ischemic myocardium and narrowing 
infarct size [5,6]. The study selected some 
patients for a clinical comparative experiment, 
aiming to discuss the effectiveness of 
intravenous thrombolysis in combination with 
nicorandil in improving reperfusion of patients 




In this study, 242 patients who suffered from 
STEMI and received thrombolytic therapy in 
Zhengzhou Central Hospital Affiliated to 
Zhengzhou University, China, between March 
2011 and March 2014, were selected. They were 
classified into observation group and control 
group. The observation group was given 20 mg 
of nicorandil (thrice daily) immediately after 
definite diagnosis, besides nicorandil; the control 
group only received thrombolytic therapy. 
Patients who showed 0.1 mV over increase (limb 
leads) or 0.2 mV over increase (precordial leads) 
in ST-segment in electrocardiogram, had newly 
emerged left bundle branch block, or had the 
disease less than 12 h before diagnosis, and had 
no contraindications to thrombolysis were 
included, while patients who were aged over 75 
years, had cardiogenic shock, were able to fulfill 
PCI within 90 min after being admitted into the 
hospital and rejected to join the study were 
excluded. This study was approved by the 
medical ethics committee of Zhengzhou Central 
Hospital Affiliated to Zhengzhou University 
(approval no. YSH20150917) and the studies 
followed guidelines of Declaration of Helsinki [7], 
and all patients each gave a signed informed 
consent. Detailed procedures for thrombolytic 
therapy were as follows. Patients were given 300 
mg of aspirin and 300 mg of clopidogrel 
immediately after being confirmed to have acute 
STEMI. For thrombolysis, (1.0 – 1.5) x 106 units 
of urokinase were added to 100 ml of normal 
saline and then the mixture was intravenously 
injected in 30 min. For patients receiving 
reteplase thrombolysis, they were intravenously 
injected with 10 mU of reteplase and then 
another 10 mU of reteplase if reperfusion did not 
occur. 
 
Indications for infarction related blood vessel 
reperfusion 
 
Thrombolysis was considered to be successfully 
performed when two of the following events 
occurred: ST segment resolution was over 50 % 
or chest pain significantly relieved in 2 h after 
thrombolysis or patients were found with 
reperfusion-induced arrhythmia. Patients whose 
treatment failed were given rescue PCI as soon 
as possible. 
 
Measurement observation index 
 
Myocardial damage degree, ST segment 
resolution, incidence of acute arrhythmia and 
cardiac function were observed when patients 
were hospitalized. Moreover, cardiac function 
and incidence of adverse cardiac events were 




SPSS19.0 software package was used for 
analyzing the data obtained. The data are 
expressed as mean ± standard deviation (SD). 
Data conforming to normal distribution was 
processed by Student’s t-test. Data at different 
time points were analyzed using analysis of 
variance test. Other data were expressed as 
percentage and processed by Chi-square test. 
Fisher exact probability method was used if 
theoretical frequency was < 5. Differences were 




Baseline data for the two groups 
 
In total, 300 patients suffering from STEMI 
received thrombolytic therapy. Of these, 52 
cases failed and 6 cases were found with 
gastrointestinal bleeding. Eventually, 128 cases 
were included into the observation group and the 
remaining 114 cases were recruited into the 
control group. We observed no statistically 
significant difference in baseline data between 
two groups. Baseline data of patients in two 
groups are shown in Table 1. 
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Comparison of cTNI level between two 
groups 
 
cTNI level was observed with no significant 
difference between two groups before treatment. 
However after thrombolytic therapy was 
performed, there was a difference between the 
groups at different time points. The difference 
between the two groups, difference at different 
time points and difference of interaction between 
groups and time points were statistically 
significant (p < 0.01); cTNI level of the 
observation group was much lower than the 
control group as shown in Table 2. 
 
Comparison of ST segment resolution 
between two groups 
 
Results of ST segment resolution observed after 
thrombolytic therapy showed that, the difference 
between the two groups, difference at different 
time points and difference of interaction between 
groups and time points were statistically 
significant (p < 0.05 or p < 0.01); ST resolution in 
the observation group was more obvious than 
that of the control group (Table 3). 
 
Comparison of incidence of arrhythmia 
between two groups 
 
Incidence of burst ventricular tachycardia and 
ventricular fibrillation in two groups was found 
with no significant difference; but incidence of 
refractory ventricular extrasystole, bradycardia 
arrhythmia and proportion of cases with 3 points 
over Curtis-Walker score in the observation 
group were all remarkably lower than those of 
the control group (p = 0.010, p = 0.020, p = 
0.014) as shown in Table 4. 
 
Table 1: Comparison of baseline data between two groups 
 
Group Control group Observation group Statistics P-value 
 (N = 114) (N = 128)   
Gender {n(%)} Male 72(63.20) 90(70.30) X2=0.412 >0.05 Female 42(36.80) 38(29.70) 
Age (years, ±SD) 60.30±11.10 58.40±11.80 t=0.909 >0.05 
Body mass index (kg/m2) 25.20±3.80 24.10±3.60 t=1.634 >0.05 
Infarction location 
{n(%)} 
Antetheca 52(45.60) 70(54.70) X2=0.663 >0.05 Non-antetheca 62(54.40) 58(45.30) 
Heart rate (time/min) 74.70±7.80 76.20±6.90 t=1.123 >0.05 
Serum creatinine (μmol/L) 80.20±12.10 79.10±14.70 t=0.446 >0.05 
Time from onset to thrombolysis (h) 3.80±1.50 3.40±1.20 t=1.627 >0.05 
Blood pressure 
(mmHg) 
Systolic pressure 130±14.60 126±15.90 t=1.435 >0.05 
Diastolic 
pressure 77±9.90 74±10.50 t=1.611 >0.05 
 
Table 2: Comparison of cTNi level between the two groups (Mean ± SD, μg / L) 
 
Group N cTNI On admission 4h 12h 24h 
Control group 114 0.90±0.35 5.8±1.4 11.4±2.7 13.2±4.2 
Observation group 128 0.80±0.31 4.0±1.5 8.3±2.8 9.8±3.9 
Between groups F=16.86 p<0.01 
Time point F=320.26 p<0.01 
Between groups & time 
point F=2.98 p<0.05 
 
Table 3: segment resolution of the two groups (mean ± SD, %) 
 
Group N  ST segment resolution 2h 4h 6h 12h 
Control group 114 41±12 46±15 58±18 72±20 
Observation group 128 44±14 52±17 69±21 80±18 
Between groups F=15.38 p<0.01 
Time point F=57.59 p<0.01 
Between groups & time point F=2.76 p<0.05 
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Group 1* 56 (49.10) 16 (14.00) 2 (1.80) 48 (42.10) 24 (21.00) 
Group 2** 32 (25.00) 6 (4.70) 0 28 (21.90) 6 (4.70) 
χ2-value 6.575 2.157 0.003 4.827 6.004 
P-value <0.05 >0.05 >0.05 <0.05 <0.05 




In recent years, the incidence of cardiovascular 
disease in China has to become higher. It has 
been reported that about 2.5 million people are 
confirmed to have acute myocardial infarction 
every year in China [8]. PCI as the optimal 
treatment method for acute myocardial infarction 
has not been widely performed due to multiple 
factors. Statistics demonstrate that, only 29, 231 
cases received PCI in China in 2013 [9]. As a 
result, most people with acute STEMI cannot be 
effectively treated by PCI at the first visit. Since 
the 1980s, several large-scale, multicentric, 
randomized and double-blinded, clinical control 
tests [10-12] have proven that, mortality of 
people who receive thrombolytic therapy for 
treating acute STEMI is 25 - 47 % lower than 
people who are given placebo, confirming the 
important position of thrombolytic therapy in the 
treatment of acute STEMI.  
 
However, thrombolytic therapy is found to be less 
effective in opening occlusive coronary artery. 
Even the third generation of thrombolytic drug 
only has a possibility of 70 % in opening 
infarction-related blood vessels and a possibility 
of 60 % in achieving TIMI3-level blood flow, and 
the drug may affect recovery of cardiac function 
[13]. Thus severe risk of myocardial ischemia 
and vascular occlusion cannot be totally avoided 
even when STEMI patients complete 
thrombolytic therapy successfully, which may not 
be beneficial for rescuing more myocardial cells 
[14]. 
 
Nicorandil is the first K (ATP) channel opener 
possessing effects similar to nitrate and being 
applied clinically [15]. Nicorandil can open K 
(ATP) channel of vascular smooth muscle, inhibit 
opening of voltage dependent Ca2+ channel as 
well as expand coronary artery and vessels 
through NO-PKG approach, thus to reduce 
microcirculation resistance, improve blood supply 
and finally lower incidence of slow coronary flow 
induced by PCI. Infarction related myocardial 
cells die in two ways; that is by necrosis and 
apoptosis [16]. Calcium overload within cells or 
mitochondria contributes to the death of 
myocardial cells [17]. It has been proved that, 
intravenous injection of nicorandil before 
angioplasty for patients with acute anterior 
myocardial infarction is more effective in 
improving left ventricular function, reducing 
malignant arrhythmia and lowering incidence of 
no-reflow phenomenon compared to angioplasty 
alone [18]. 
 
This study showed that, taking nicrorandil before 
thrombolytic therapy could also reduce 
myocardial damage induced by ischemia, relieve 
left ventricular wall motion, lower incidence of 
arrhythmia and improve cardiac function. Earlier 
studies [19,20] demonstrate that, amplitude and 
speed of ST segment resolution after 
thrombolysis can reflect effect of myocardial 
perfusion; amplitude of ST segment resolution is 
in a significant correlation to of left ventricle 
contraction; rapider ST segment resolution 
indicates better myocardial perfusion. In this 
study, ST segment in the observation group 
declined rapidly and significantly, indicating that 
nicrorandil could further improve myocardial 
perfusion level as well as prognosis of STEMI 
patients. 
 
Limitations of the study 
 
In the observation group, the incidence of 
adverse cardiac events did not show significant 
decline, which may be correlated to the small 
size of samples. The current study with small 
sample size cannot be used for evaluating 
effects of nicrorandil on cardiac events. Though 
there is a trend, the difference was not 
statistically significant. Therefore, a further study 




Intravenous thrombolysis in combination with oral 
administration of nicrorandil can further enhance 
myocardial reperfusion level, improve heart 
function and lower incidence of arrhythmia. It is 
of great significance to improve long-term 
prognosis and living quality of STEMI patients. 
Hence, the therapy strategy is worth applying in 
clinical practice. 
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